MedTrace Logo

Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple Sclerosis

NCT00599274 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 136

Last updated 2010-01-27

No results posted yet for this study

Summary

The purpose of this study is to find out if weekly Avonex works as well as three times a week Rebif in subjects with relapsing multiple sclerosis.

Conditions

Interventions

DRUG

Interferon beta-1a

injection once a week

DRUG

Interferon beta-1a

injection three times a week

Sponsors & Collaborators

Principal Investigators

  • Biogen-Idec Investigator · Biogen

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-08-31
Completion
2003-05-31

Countries

  • United States
  • Australia
  • Austria
  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00599274 on ClinicalTrials.gov